#USA #North Chicago #Allergan Aesthetics #TrenibotulinumtoxinE #AAD 2026

Allergan Aesthetics Highlights Safety and Efficacy of TrenibotE

At the recent 2026 American Academy of Dermatology (AAD) meeting, Allergan Aesthetics, part of AbbVie, showcased new groundbreaking research on the investigational neurotoxin TrenibotulinumtoxinE (TrenibotE). This innovative treatment aims to enhance patient satisfaction by addressing common aesthetic concerns, particularly glabellar lines, also known as frown lines. The company presented four insightful posters that collectively offer substantial evidence around the safety, efficacy, and emerging trends in aesthetic treatments amidst a growing population of patients seeking aesthetic enhancements.

Key Findings from the AAD Presentation

The findings presented at the AAD meeting underline the positive impact of TrenibotE, which is characterized by its fast onset of action and favorable safety profile across diverse patient demographics. According to John Maltman, Ph.D., vice president of global aesthetics medical affairs at Allergan Aesthetics, this research reinforces trust in the brand's extensive product offerings.

TrenibotE Effectiveness and Safety

In a pivotal phase 3 open-label study involving repeat treatments for glabellar lines, TrenibotE demonstrated a consistent safety profile without the development of neutralizing antibodies across up to three treatments. Remarkably, results can be observed as quickly as eight hours after the administration, offering patients rapid improvement in their appearance, with effects typically lasting between two to three weeks.

Highlights from the Study Include:

• - Rapid Onset: Significant reduction in glabellar line severity observed within hours.
• - Well-tolerated: The treatment was well-tolerated, showing no new safety issues.
• - Efficacy/Consistency: Outcomes remained consistent over multiple sequential treatments, as confirmed by both the investigator and participant assessments.

Aesthetic Concerns Among GLP-1 Treated Patients

Allergan also presented data about the evolving demographics of aesthetic treatments, particularly focusing on patients undergoing GLP-1 agonist therapy for medical weight loss. An increasing number of individuals in this category are expressing concerns about their facial appearance as they continue their treatment journey.

Key insights from this survey include:

• - Surge in Aesthetic Interest: Approximately 52% of patients undergoing GLP-1 treatment report dissatisfaction with their face's aesthetics.
• - Barriers to Treatment: Key hurdles preventing these patients from pursuing aesthetic interventions include the high costs (82%) and anxiety regarding the unnatural results (58%).
• - Demographic Insights: The patients receiving these treatments are predominantly white, younger women aged between 30-49.

Conclusion

With the evolution of patient profiles and their aesthetic needs, Allergan Aesthetics is well-positioned to cater to this burgeoning demand within the aesthetics industry. The research highlights presented at the AAD serve to reinforce the company’s commitment to safety and efficacy in all its offerings. The final approval of TrenibotE could mark a revolutionary addition to the neurotoxin landscape, potentially changing the way aesthetic treatments are approached in the coming years. For further details about the findings and a complete overview of the presented e-posters, visit Allergan Aesthetics.

About Allergan Aesthetics

As a division of AbbVie, Allergan Aesthetics is dedicated to providing innovative and effective solutions in aesthetics. The company is committed to advancing research and development, ensuring that patients receive the best possible care. For additional information on Allergan Aesthetics and its array of innovative products, navigate to their official website.